Our fair value estimate for WuXi is HKD 24.60 per share. WuXi has been growing at a CAGR of 53.3% for the past eight years. Although its USD 20.5 billion total backlog revenue supports our growth ...

Professor Jae-Byum Chang and Professor Yeon Sik Jung's joint research team of the Department of Materials Science and ...

Synaffix adds to the flurry of ADC dealmaking as it partners with Boehringer and Mitsubishi Tanabe with deals announced on the same day.

Respiratory illnesses are on the rise across San Antonio, Bexar County and Texas. Doctor Jason Bowling, a professor and infectious diseases specialist at UT Health San Antonio and the Chief ...

The application is supported by data from the randomized, double-blind, placebo-controlled phase 3 Vivacity-MG3 study.

Johnson & Johnson has won Food and Drug Administration priority review for its application seeking approval of nipocalimab in certain patients with generalized myasthenia gravis.

Vir Biotechnology's recent share price rally is driven by their promising cancer program. Having shot to over a $1.5B market ...

RQ Bio welcomes positive CHMP opinion on Kavigale for prevention of COVID-19 in immunocompromised individualsKavigale (sipavibart; AZD3152) is a ...

We’ll do an IgE test to figure out what’s causing those reactions.” When my doctor said those words, I nodded like I knew ...

To identify this year’s Drugs to Watch 2025 list, Clarivate drew from expertise from over 160 Clarivate analysts covering ...

Subcutaneous ocrelizumab (SC OCR) was found to be safe for patients with relapsing and primary progressive multiple sclerosis ...

Five years on from the first news of COVID, recent reports of an obscure respiratory virus in China may understandably raise ...